{"cdcTestId":"2020-0013","testcaseName":"2nd dose of Pfizer Covid-19 Vaccine at 21 - 5 days ","vaccineGroup":"COVID-19","evaluationTestType":"All Valid Forecast Test","forecastTestType":"Recommended based on minimum interval from invalid dose","assessmentDate":"2022-10-19T00:00:00","patient":{"dob":"1986-09-28T00:00:00","gender":"F"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2022-09-28T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-14T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Not Valid","evaluationReason":"Interval: too short"}]},"forecast":{"forecastNum":"2","earliestDate":"2022-11-04T00:00:00","recommendedDate":"2022-11-04T00:00:00","pastDueDate":"2022-12-08T00:00:00"},"doses":[{"dateAdministered":"2022-09-28T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-14T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Not Valid","evaluationReason":"Interval: too short"}],"dateAdded":"2020-10-06T20:00:00","dateUpdated":"2022-09-27T09:05:00.856","generalDescription":"This test case describes when a patient is administered the second dose of the Pfizer Covid-19 vaccine at 21-5 days after the first dose, and after the 10/24/2021 cessation date, that the dose is not valid. A repeat dose should be forecast.","changedInVersion":"4.21","reasonForChange":"v4.21 - Updated past due date to 8 weeks per Clinical Consideration guidance 02/22/22.\nv4.14 - added past due date.\nv4.13 - Updated test case to include ACIP recommendation where if a second dose of a MRNA Covid-19 vaccine is given earlier than the 4-day grace period, and after the 10/24/2021 cessation date, that a repeat dose should be forecast."}